CompletedNot Applicable

A Retrospective Review of DEXTENZA 0.4 mg inseRt Following Corneal Transplant or Cataract Surgery

United States25 participantsStarted 2021-03-09

Plain-language summary

A Retrospective Review of Pain and Inflammation Resolution Outcomes in Patients Who Received DEXTENZA Intracanalicular Dexamethasone (0.4 mg) Insert Prior to or Following Corneal transplant or Cataract surgery

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Age 18 years and older * Patients who received DEXTENZA insertion perioperatively. Exclusion Criteria: * Any patient who did not receive DEXTENZA insertion

What they're measuring

Mean change in pain score

Timeframe: Assessed for 3 months after drug insertion

Mean change in inflammation (Cell and Flare) scores

Timeframe: Assessed for 3 months after drug insertion

Trial details

NCT IDNCT04975971

SponsorNicole Fram M.D.

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2021-05-19

View on ClinicalTrials.gov More Anterior Chamber Inflammation trials